EU/3/12/1089

About

On 24 January 2013, orphan designation (EU/3/12/1089) was granted by the European Commission to Medical Need Europe AB, Sweden, for choline tetrathiomolybdate for the treatment of Wilson's disease.

The sponsorship was transferred to Wilson Therapeutics AB, Sweden, in July 2014.

Key facts

Active substance
Choline tetrathiomolybdate
Disease / condition
Treatment of Wilson's disease
Date of decision
24/01/2013
Outcome
Positive
Orphan decision number
EU/3/12/1089

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Wilson Therapeutics AB
Kungsgatan 3
SE-111 43 Stockholm
Sweden
Tel. +46 8796 0000
E-mail: info@wilsontherapeutics.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating